General
Preferred name
Remdesivir
Synonyms
GS-5734 ()
Remdesivir (GS-5734) ()
Veklury ()
GS 5734 ()
Remdesivir-d4 ()
P&D ID
PD122226
CAS
1809249-37-3
2738376-82-2
Tags
available
prodrug
drug
Approved by
PMDA
EMA
FDA
First approval
2020
Drug Status
investigational
approved
Drug indication
Coronavirus Disease 2019 (COVID-19)
Ebola virus infection
Severe acute respiratory syndrome (SARS)
Middle East Respiratory Syndrome (MERS)
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Remdesivir (GS-5734) is a nucleotide analogue drug that was developed by Gilead Sciences for antiviral potential, in particular for anti-Ebola and anti-Marburg virus activity . It acts is an inhibitor of the viral RNA-dependent RNA polymerase (RdRP) that functions as a chain terminator during viral RNA synthesis. Remdesivir is a prodrug whose major active metabolite is . Its 1'-CN group and C-linked nucleobase ensure optimal anti-Ebola potency and selectivity against host polymerase enzymes. Remdesivir has broad-spectrum activity against several viral families such as filoviruses, paramyxoviruses, and coronaviruses, and including the SARS and MERS coronaviruses (CoVs), endemic circulating human CoVs, and against SARS-CoV-2 . The first patient to test positive for SARS-CoV-2 in the US was treated with i.v. remdesivir (using compassionate use of an investigational therapy prescribing) and his clinical condition improved significantly within the next 24h without observation of adverse effects .
(GtoPdb)
DESCPRITION
Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity. Remdesivir has demonstrated in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are also coronaviruses and are structurally similar to COVID-19. The limited preclinical data on remdesivir in MERS and SARS indicate that remdesivir may have potential activity against COVID-19
DESCRIPTION
Viral RNA-dependent RNA polymerase (RdRP) inhibitor; broad spectrum antiviral nucelotide
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
10
Compound Sets
17
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Selleckchem Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
24
Molecular Weight
602.23
Hydrogen Bond Acceptors
13
Hydrogen Bond Donors
4
Rotatable Bonds
13
Ring Count
4
Aromatic Ring Count
3
cLogP
2.31
TPSA
203.55
Fraction CSP3
0.48
Chiral centers
6.0
Largest ring
6.0
QED
0.16
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Primary Target
RNA Polymerase
MOA
Inhibitor
Target
EBOV inhibitor
DNA/RNA Synthesis
SARS-CoV
Antiviral,COVID-19,DNA/RNA Synthesis
Therapeutic Class
Antiviral Agents
Pathway
Anti-infection
Cell Cycle/DNA Damage
Source data
